JP Morgan Says Jazz Positioned For 'Organic Growth and Acquisition'

Loading...
Loading...

Shares of Jazz Pharmaceuticals JAZZ are up almost 20 percent over the past five trading sessions.

JP Morgan started coverage of the company with an overweight rating and $190 price target.

“In the context of an ongoing wave of consolidation in the specialty pharmaceuticals sector, we see Jazz as well positioned from both an organic growth and acquisition standpoint,” writes analyst Jessica Fye.

Related: Leerink Says Tekmir Is 'Uniquely Positioned'

JP Morgan further comments that the company is diversifying away from from its core asset with acquisitions. The company has a borrowing allowance of $3 billion.

On Tuesday, Dow Jones reported Allergan AGN is interested in purchasing Salix Pharmaceuticals SLXP, a competitor in the acquisition space. This news moved Jazz almost four percent higher to $158.14.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsJessica FyeJP Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...